CrossAssetDataThe Company File
···
NVCR

NovoCure Limited

NovoCure Limited is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841). In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $655 million and a loss of $136 million (its filed statements).

Product business Surgical & Medical Instruments & Apparatus filings since 2015 8 of 9 filed, 1 estimated
Ask the desk about NVCR → Compare NVCR with ATEC → Price chart on TradingView ↗ Full EDGAR file ↗ Watch NVCR →

Sector peers: ATECOFIXTNDMAORT

5.2/10headline grade
vs its business-model standard
5.5/10past 5.1/10present 4.9/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.2 out of ten, 8 of 9 metrics filed and 1 estimated: past 5.5 out of ten, present 5.1 out of ten, future 4.9 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 4.6 out of ten. 1 warning event since 2017; the latest 2020-08-06. 46th percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 6.2 out of ten. +25.8% a year over 10 filed years; profitable in 1 of 10. 61st percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 5.5 out of ten. CrossAssetData estimate 5.5/10, confidence 35 of 100 (one part). 55th percentile among 119 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Financial health (present): 5.5 out of ten. ROE -40%: lost 40¢ per shareholder dollar. Leverage 58%: owes 58¢ per asset dollar. 55th percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 5.5 out of ten. top 45% of 109 in its family; net margin -20.8%. 55th percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 3.8 out of ten. bottom 38% of 90 in its family for leadership; chief executive since 2026. 38th percentile among 90 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 5.5 out of ten. top 45% of 104 in its family for room to expand. 55th percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 3.9 out of ten. bottom 39% of 105 in its family for growth drivers. 39th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 5.3 out of ten. top 48% of 88 in its family for expectations against reality. 52nd percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-23 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-23 (on EDGAR). Newest filing: Form 8-K, 2026-10-01. Filings on record since 2015. Read from EDGAR 2026-10-12.

Where the revenue comes from

By geography: United States 59%, Germany 12%, France 12%, Other international markets 9%, Japan 6%, China 3%. As tagged in its annual report (Form 10-K, filed 2026-02-26).

Who runs it

Danziger, Asaf (Chief Executive Officer); Leonard, Frank X (Chief Executive Officer); Cordova, Ashley (Former Chief Executive Officer); Doyle, William F (Executive Chairman); Brackmann, Christoph (Chief Financial Officer); Paravasthu, Mukund (Chief Operating Officer); Puri, Michal Nath (Chief Human Resources Officer); Leupin, Nicolas (Former Chief Medical Officer); Ben, Arye Barak (General Counsel); Weinberg, Uri (Chf Medical and Innovation Ofr); and 8 more. 18 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.